Dexcom (DXCM) Liabilities and Shareholders Equity (2010 - 2026)

Dexcom (DXCM) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $6.5 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 11.9% year-over-year to $6.5 billion; the TTM figure through Jun 2026 stood at $26.9 billion (changed 0.04% YoY), while the FY2025 annual figure was $6.3 billion, down 2.23% from the prior year.
• Liabilities and Shareholders Equity declined to $6.5 billion in Q2 2026 per DXCM's latest filing, from $6.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $7.5 billion in Q3 2025 and bottomed at $4.9 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $6.3 billion across 5 years, with a median of $6.5 billion in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 34.64% — and 2026, when it slipped 11.9%.
• Dexcom's Liabilities and Shareholders Equity stood at $5.4 billion in 2022, then rose by 16.19% to $6.3 billion in 2023, then rose by 3.51% to $6.5 billion in 2024, then dropped by 2.23% to $6.3 billion in 2025, then rose by 1.82% to $6.5 billion in 2026.
• Business Quant data shows DXCM's Liabilities and Shareholders Equity at $6.5 billion in Q2 2026, $6.6 billion in Q1 2026, and $6.3 billion in Q4 2025.